Physician profile
Vijay N Kumar
NPI 1477747145
$3,484.23
in general payments reported to CMS, 2019-2025
29 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $610 · 2021: $457 · 2022: $534 · 2023: $469 · 2024: $587 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $359.25 | 2021-2024 | |
| Novo Nordisk INC | $329.74 | 2019-2024 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $315.34 | 2020-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $311.99 | 2019-2022 | |
| Abbvie INC. | $295.79 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.43 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Xeris Pharmaceuticals, INC. | $219.52 | 2022-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $196.47 | 2019-2023 | |
| Axsome Therapeutics, INC. | $158.95 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $130.01 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $120.74 | 2020-2024 | Mounjaro, Zepbound |
| Sunovion Pharmaceuticals INC. | $117.21 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $100.08 | 2021-2024 | |
| Pfizer INC. | $89.32 | 2019-2023 | |
| Amgen INC. | $74.94 | 2023-2024 | Repatha, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $63.41 | 2019-2021 | |
| Amarin Pharma, INC. | $56.78 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $48.29 | 2020-2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $43.47 | 2025 | Nuzyra, Xhance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.09 | 2024-2025 | Caplyta |
| Galderma Laboratories, L.P. | $34.84 | 2022-2023 | |
| Abbott Laboratories | $32.79 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.02 | 2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.66 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.22 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.75 | 2025 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $14.43 | 2021 | |
| Exact Sciences Corporation | $14.37 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $14.33 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.